1 active not recruiting, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Vamifeport: new trials by email Literature Review of Vamifeport trials Research Report on Vamifeport
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Phase 2 | Active not recruiting | CSL Behring | 84 | 2026-01-22 | 2026-10-21 |
| Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg - Sickle Cell Disease | Phase 2 | Completed | Vifor (International) Inc. | 25 | 2021-11-18 | 2025-02-18 |
Anemia (1) · Anemia, Sickle Cell (1) · Hemochromatosis (1) · Iron Overload (1)
CSL Behring (1) · Vifor (International) Inc. (1)
France (2) · United Kingdom (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Ireland (1) · Italy (1) · Lebanon (1) · Netherlands (1)
2025 (1)